Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sleep studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSleepSleep (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Hospitalization 36% Hospitalization (b) 21% Sleep for COVID-19  Li et al.  Prophylaxis Is better sleep beneficial for COVID-19? Retrospective 46,535 patients in the USA (March - December 2020) Lower mortality (p=0.017) and hospitalization (p=0.008) c19early.org Li et al., Sleep, June 2021 Favors good sleep Favors control

Poor sleep behavior burden and risk of COVID-19 mortality and hospitalization

Li et al., Sleep, doi:10.1093/sleep/zsab138
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Sleep for COVID-19
16th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.0000000019 from 15 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
UK Biobank retrospective, 46,535 participants with sleep behavior assessed between 2006 and 2010, showing higher risk of hospitalization and mortality with poor sleep.
risk of death, 43.2% lower, OR 0.57, p = 0.02, inverted to make OR<1 favor higher quality sleep, fully adjusted model C, significant poor sleep burden, RR approximated with OR.
risk of hospitalization, 35.9% lower, OR 0.64, p = 0.008, inverted to make OR<1 favor higher quality sleep, fully adjusted model C, significant poor sleep burden, RR approximated with OR.
risk of hospitalization, 21.3% lower, OR 0.79, p = 0.02, inverted to make OR<1 favor higher quality sleep, fully adjusted model C, moderate poor sleep burden, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 18 Jun 2021, retrospective, USA, peer-reviewed, mean age 69.4, 8 authors, study period March 2020 - December 2020. Contact: pli9@bwh.harvard.edu, khu1@bwh.harvard.edu, lgao@mgh.harvard.edu.
This PaperSleepAll
Abstract: SLEEPJ, 2021, 1–3 doi: 10.1093/sleep/zsab138 Advance Access Publication Date: 18 June 2021 Letter to the Editor Letter to the Editor Peng Li1,2,*, , Xi Zheng1, Ma Cherrysse Ulsa1, Hui-Wen Yang1, Frank A. J. L. Scheer1,2,3, , Martin K. Rutter4, Kun Hu1,2,3,*,†, and Lei Gao1,2,5,*,†, Medical Biodynamics Program, Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, USA, 2Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA, 3Medical Chronobiology Program, Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, USA, 4Division of Diabetes, Endocrinology & Gastroenterology, University of Manchester, Manchester, UK and 5Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 1 Contributed equally. *Corresponding author. Peng Li, Kun Hu, or Lei Gao, Medical Biodynamics Program, Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA 02115, USA. Email: pli9@bwh.harvard.edu; khu1@bwh.harvard.edu; lgao@mgh.harvard.edu. † Dear Editor, Despite the unprecedented efforts in vaccinations, the COVID19 pandemic will likely continue to affect those most vulnerable [1], and the need to identify modifiable risk factors remains [2]. Poor sleep behavior traits have been linked to multisystemic disruptions [3], but whether this is linked to COVID-19 severity remains unknown. Using, the UK Biobank, a population-based cohort of >500 000 participants recruited between 2006 and 2010 [4], we determined the associations of poor sleep behavior burden with mortality, and need for hospitalization after a positive COVID-19 result. This study was restricted to 46 535 participants tested between March and December 2020 (age: 69.4 ± 8.3 years [mean ± standard deviation]; female: 53.3%). Sleep behavior traits (duration, daytime sleepiness, insomnia, and chronotype) were assessed between 2006 and 2010. Scores of 0 (if sleep duration between 6 and 9 h, “never/rarely” daytime sleepiness/insomnia, or non-evening chronotype), 1 (if short <6 h, or long sleeper >9 h, “sometimes” experience daytime sleepiness/insomnia, or evening chronotype), and 2 (if “often/all the time” experience daytime sleepiness, or “usually” have insomnia) were assigned, and summed to obtain a sleep behavior score ranging from 0 to 6, where higher scores are indicative of multiple domains of poor sleep behavior traits. We used this to classify poor sleep behavior burden as follows: “none” (0), “mild” (1), “moderate” (2–3), and “significant” (4–6). 8422 participants tested positive (COVID+), defined as the earliest result from PCR tests, provided by Public Health England. If tested but never positive (COVID−; n = 38 113), the earliest test date was used. Primary outcome was 30-day mortality, matched to death registry dates. The interaction effect between sleep behavior burden and COVID positivity/negativity on mortality was also tested. Finally, hospitalization within 7 days of a positive test was extracted by matching dates with hospital admission data (7146 positive cases available). We included test results that were reported up to 4 days after death or hospitalization, per the UK Biobank’s guidance over testing-to-result time frames; thus, we excluded 11 participants with a date of death and/or hospitalization more than 4 days before test results were released. Logistic regression models were used to determine the..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit